Relativity Healthcare Partners

Michael Chao serves as Founder and Senior Managing Director, leading the firm's investment strategy and decision-making. Alfonso Chang is a Managing Director and appears to manage day-to-day operations, including his role as CEO of the firm's affiliate Parsolex. The firm's lean team structure concentrates investment authority with Chao, supported by the broader Chao family's network in pharmaceuticals and healthcare.

Relativity Healthcare Partners was founded by Michael Chao, whose father is Allen Chao, founder of Watson Pharmaceuticals. Watson, now part of Teva following a $40.5 billion acquisition of Allergan's generics business, originated as a small California-based generic drug manufacturer. The Chao family's operational experience scaling Watson into a major industry player directly informs Relativity's investment philosophy and its ability to advise portfolio companies on regulatory and commercial pathways.

Relativity Healthcare Partners typically invests as a co-investor alongside specialized healthcare venture firms and corporate venture arms. In the OrphoMed investment, it partnered with Takeda Ventures and Pappas Capital. In LensGen's Series A, it invested alongside the Hoya Group. The firm's syndication pattern suggests it builds consortiums around promising assets rather than leading and pricing rounds independently.

Relativity targets early-stage, expansion-stage, and growth-stage healthcare companies. Its portfolio spans biopharmaceuticals, medical devices, and potentially digital health. The firm's co-investment with Takeda Ventures in OrphoMed demonstrates a willingness to engage with clinical-stage drug development, while LensGen represents a medical device play in the ophthalmology space.

Relativity Healthcare Partners is structured as an investment firm, distinct from the Chao family's broader holding entities like MAL Investment and Newport Healthcare Advisors. While the precise capital base is not publicly disclosed, the firm participates in syndicated venture rounds alongside institutional investors, indicating it operates with a degree of independence from purely internal family capital. The designation as a generalist asset manager suggests a mandate that may include external limited partners or a permanent capital vehicle.

The Chao family maintains separate philanthropic structures, including involvement with the CHOC (Children's Hospital of Orange County) Foundation and the CUNY SPH Foundation. These entities are distinct from Relativity Healthcare Partners' investment operations, representing the family's charitable commitments in pediatric healthcare and public health education. No evidence suggests Relativity itself manages program-related investments or impact-linked capital.

Relativity's edge lies in the Chao family's direct operational history with Watson Pharmaceuticals, a generics company that grew through aggressive consolidation and manufacturing scale. For portfolio companies, this translates into practical guidance on FDA regulatory strategy, manufacturing process optimization, and potential exit pathways to larger pharmaceutical acquirers. This operator-first lens is reinforced by Alfonso Chang's dual role as CEO of Parsolex, a separate operating entity.